What is NeoGenomics's G&A?

NeoGenomics (NEO) reported G&A of $65.74M in Q1 2026.

How has NeoGenomics's G&A changed year-over-year?

NeoGenomics's G&A decreased by 3.6% year-over-year, from $68.21M to $65.74M.

What is the long-term trend for NeoGenomics's G&A?

Over 4 years (2021 to 2025), NeoGenomics's G&A has grown at a 5.4% compound annual growth rate (CAGR), from $221.35M to $273.34M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

NeoGenomics NEO G&A

G&A at other companies

Guardant HealthGH

$57.93M+23.4%

ImmunomeIMNM

$12.95M+21.1%

CareDxCDNA

$30.48M+33.9%

VeracyteVCYT

$23.68M-30.0%

Cullinan Therapeutics, Inc.CGEM

$11.57M-14.5%

Other financials

Income statement

See full

Revenue$186.7M+11.1%

Gross profit$80.9M+10.4%

Operating income-$18.2M+34.4%

Net income-$17.1M+34.0%

EPS (diluted)-$0.13+35.0%

Balance sheet

See full

Cash & equivalents$146.1M-57.8%

Total debt$66.3M+5.3%

Total equity$828.8M-6.7%

Total assets$1.3B-15.9%

Cash flow

See full

Operating cash flow-$8.1M+67.9%

CapEx$5.0M+11.1%

Free cash flow-$13.1M+56.0%

Valuation

See full

Market cap$1.68B+86.5%

Enterprise value$1.6B+159%

P/S2.3×+0.9×

Profitability

See full

Gross margin43.2%-1.1pp

Operating margin-14.2%+1.1pp

Net margin-13.3%+2.4pp

FCF margin-4.9%—

Returns & leverage

See full

Return on equity-11.6%+6.2pp

Debt / equity0.1×0.0×

Current ratio4.4×+2.4×

Where this comes from

Reported directly by NeoGenomics in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: NeoGenomics’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about NeoGenomics's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is NeoGenomics's G&A?: NeoGenomics (NEO) reported G&A of $65.74M in Q1 2026.
How has NeoGenomics's G&A changed year-over-year?: NeoGenomics's G&A decreased by 3.6% year-over-year, from $68.21M to $65.74M.
What is the long-term trend for NeoGenomics's G&A?: Over 4 years (2021 to 2025), NeoGenomics's G&A has grown at a 5.4% compound annual growth rate (CAGR), from $221.35M to $273.34M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.